The need for pediatric clinical pharmacology research and training has never been greater. The T32 Training Program in Pediatric Clinical Pharmacology at Cincinnati Children's Hospital Medical Center (CCHMC) is designed specifically to address this critical need. The program is based in the Division of Clinical Pharmacology, which is jointly a unit within the Department of Pediatrics and the University of Cincinnati, College of Medicine (UCCOM). This T32 Training Program also involves strong collaborations with the James L. Winkle College of Pharmacy and the Departments of Pharmacology & Cell Biophysics and Biomedical Informatics at the UCCOM. The program outlined in this renewal application draws on strong leadership and a diverse group of well-established faculty mentors actively involved in clinical pharmacology research representing 12 divisions within the Department of Pediatrics and 4 Departments at the University of Cincinnati. The program has strong institutional support and takes advantage of a variety of advanced technologies and resources within a uniquely collaborative environment. The T32 training program is innovative and well aligned with the objectives outlined in the program announcement as it: (1) has a focus in early and later phase studies in multiple and diverse pediatric populations through ongoing research collaborations with all major pediatric subspecialties; (2) involves the application and development of innovative quantitative methodologies such as physiologically based PK/PD modeling, systems pharmacology and quantitative modeling and simulation and in silico clinical trial design; (3) is embedded in the institutional and Academic Health Center's pharmacogenetic/genomics research and training endeavors of the Center for Pediatric Genomics; (4) is closely integrated with Bioinformatics and Health Services and Outcomes Research; (5) can rely on over ten years of experience as one of 13 sites of the Pediatric Pharmacology Research Unit (PPRU) network, and on one funding cycle as a successful training program. The program provides a unique training experience and has successfully opened new avenues to enlarge the pool of talented young clinical investigators with a career interest in pediatric therapeutics. The training program allows postdoctoral fellows to acquire a refined vision for applying state of the art principles of pediatrics clinical pharmacology to clinical research and evidence- based practice with the goal to improve therapeutics and health outcomes in children.

Public Health Relevance

The T32 Training Program in Pediatric Clinical Pharmacology provides an outstanding resource for expanding and improving the current critically small pool of pediatric clinical pharmacologists by training the next generation of pediatric clinical investigators to assume leadership roles in developing innovative, high impact clinical and developmental pharmacology related approaches that will improve proper use of medicines in children. This will allow the further enhancement of personalized pediatric therapeutics and ultimately improve the quality of care and related health outcomes of children.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Institutional National Research Service Award (T32)
Project #
5T32HD069054-10
Application #
9918428
Study Section
Special Emphasis Panel (ZHD1)
Program Officer
Pawlyk, Aaron C
Project Start
2011-05-16
Project End
2021-04-30
Budget Start
2020-05-01
Budget End
2021-04-30
Support Year
10
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Emoto, Chie; Johnson, Trevor N; McPhail, Brooks T et al. (2018) Using a Vancomycin PBPK Model in Special Populations to Elucidate Case-Based Clinical PK Observations. CPT Pharmacometrics Syst Pharmacol 7:237-250
Dong, Min; Fukuda, Tsuyoshi; Selim, Sally et al. (2017) Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents. Clin Pharmacokinet 56:1207-1217
Dong, Min; Mizuno, Tomoyuki; Vinks, Alexander A (2017) Opportunities for model-based precision dosing in the treatment of sickle cell anemia. Blood Cells Mol Dis 67:143-147
Downes, Kevin J; Dong, Min; Fukuda, Tsuyoshi et al. (2017) Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. J Antimicrob Chemother 72:254-260
Hahn, Andrea; Fukuda, Tsuyoshi; Hahn, David et al. (2016) Pharmacokinetics and pharmacogenomics of ?-lactam-induced neutropenia. Pharmacogenomics 17:547-59
Downes, Kevin J; Abulebda, Kamal; Siracusa, Christopher et al. (2016) Non-typeable Haemophilus influenzae purulent pericarditis in a child with cystic fibrosis. Pediatr Int 58:607-9
Downes, Kevin J; Goldstein, Stuart L; Vinks, Alexander A (2016) Increased Vancomycin Exposure and Nephrotoxicity in Children: Therapeutic Does Not Mean Safe. J Pediatric Infect Dis Soc 5:65-7
Dong, Min; McGann, Patrick T; Mizuno, Tomoyuki et al. (2016) Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. Br J Clin Pharmacol 81:742-52
Ngamprasertwong, Pornswan; Dong, Min; Niu, Jing et al. (2016) Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. PLoS One 11:e0146563
Hahn, Andrea; Frenck Jr, Robert W; Zou, Yuanshu et al. (2015) Validation of a pediatric population pharmacokinetic model for vancomycin. Ther Drug Monit 37:413-6

Showing the most recent 10 out of 19 publications